Global pharma major Lupin Limited (Lupin) today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Tenofovir Alafenamide Tablets, 25 mg, to market a generic equivalent of Vemlidy® Tablets, 25 mg, of Gilead Sciences, Inc. (Gilead). This product will be manufactured at Lu pin's Nagpur facility in India.
Tenofovir Alafenamide Tablets (RLD: Vemlidy® Tablets) had estimated annual sales of USD484.2 million in the U.S. (IQVIA MAT December 2021)
Shares of Lupin Limited was last trading in BSE at Rs. 772.35 as compared to the previous close of Rs. 773.70. The total number of shares traded during the day was 49690 in over 2370 trades.
The stock hit an intraday high of Rs. 779.40 and intraday low of 765.80. The net turnover during the day was Rs. 38415983.00.